The ACTC1 Knockout 769-P Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 769-P human renal epithelial cell line. This product provides a loss-of-function model for ACTC1, the gene encoding alpha-cardiac actin. Through CRISPR/Cas9-mediated gene disruption, the target locus is modified across the polyclonal population, enabling pooled functional studies without isolation of single-cell clones. The polyclonal format preserves cellular heterogeneity while introducing targeted mutations in ACTC1, offering a versatile tool for examining gene function in a cancer-relevant background.
The 769-P cell line is a well-established model originating from a primary clear cell adenocarcinoma of the kidney. These adherent epithelial cells retain key features of renal cell carcinoma (RCC), including dysregulated proliferative and migratory signaling pathways. As a widely utilized RCC model, 769-P cells recapitulate aspects of tumor biology such as anchorage-independent growth and invasive potential. The host cell background thus provides a clinically relevant context for interrogating the role of ACTC1 in kidney cancer pathogenesis and actin-dependent cellular processes.
ACTC1 encodes alpha-cardiac actin, a sarcomeric thin filament component also ectopically expressed in renal carcinomas. It polymerizes into F-actin, contributing to cytoskeletal organization. Transcription is regulated by SRF/MRTF complexes downstream of RhoA and mechanical stretch, with additional modulation by TGF-beta. ACTC1 interacts with tropomyosin, cofilin, profilin, alpha-actinin, and vinculin to coordinate actin dynamics and focal adhesion linkage. RhoA-ROCK-LIMK signaling controls cofilin-mediated actin turnover, while FAK and paxillin mediate adhesion signaling. In cancer cells, ACTC1 may promote migration and invasion by regulating cytoskeletal remodeling and focal adhesion dynamics.
In the 769-P renal carcinoma line, ACTC1 knockout enables dissection of alpha-cardiac actin??s contribution to oncogenic phenotypes. Loss of ACTC1 is expected to impair actin cytoskeleton integrity, potentially reducing cell motility, invasion, and adhesion signaling. This model is particularly relevant given the emerging link between aberrant actin isoform expression and tumor progression. By abrogating ACTC1 expression, researchers can investigate how cardiovascular actin isoforms influence renal cancer cell behavior, including potential cross-talk with Hippo and integrin pathways. The polyclonal knockout population allows for robust assessment of ACTC1??s role in a heterogeneous cell context, mirroring tumor heterogeneity.
Researchers may employ this product to explore non-muscle functions of cardiac actin, serving as a negative control for cardiac-specific studies or to investigate actin-mediated signaling in carcinoma. Representative assays include RT-qPCR and Western blotting to confirm knockout, immunofluorescence for F-actin to visualize cytoskeletal changes, Transwell migration and wound healing assays to measure motility, co-immunoprecipitation to assess protein interactions, and RNA-seq for transcriptomic profiling. For further details on product specifications and experimental support, please contact Ascent Research.
